Otsuka and Lundbeck report phase III data evaluating brexpiprazole for the treatment of manic episodes associated with bipolar I disorder (56KB)
(WorldNews Japan)

February 15, 2019 Company Name Otsuka Holdings Co., Ltd. Name of Representative Tatsuo Higuchi President and Representative Director, CEO Code Number 4578, First Section of the Tokyo Stock Exchange Contact Yuji Kogure Director, Investor Relations Department (Phone: +81-3-6361-7411) Otsuka and Lundbeck report phase III data evaluating brexpiprazole for the treatment of manic episodes associated with bipolar I disorder o The efficacy of brexpiprazole for the acute treatment of manic episodes, with or without mixed features, in subjects with bipolar I disorder was investigated in two three-week, double-blind, placebo-controlled trials o The studies did not meet the primary endpoint of...